Skip to main content
Clinical Trials/NCT02660333
NCT02660333
Completed
Not Applicable

Effect of Prebiotic or Synbiotic Supplementation on Inflammatory Response and Indicators of Nutritional Status in Individuals With Morbid Obesity: A Randomized Clinical Trial, Placebo-controlled and Triple Blind

Universidade Federal de Santa Catarina1 site in 1 country22 target enrollmentJanuary 2016
ConditionsMorbid Obesity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Morbid Obesity
Sponsor
Universidade Federal de Santa Catarina
Enrollment
22
Locations
1
Primary Endpoint
Cytokines
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the effect of prebiotic or synbiotic supplementation on inflammatory response and indicators of nutritional status in patients with morbid obesity. Study hypothesis: Supplementation of 12 g/day of fructooligosaccharides (prebiotic) or 12 g/day of fructooligosaccharides + strains of lactobacilli and bifidobacteria (synbiotic) during 30 days promotes reduction of plasma/serum levels of acute phase proteins, cytokines, metabolic and anthropometric parameters in individuals with BMI ≥ 40kg/m².

Detailed Description

The purpose of this study is to evaluate the effect of prebiotic or synbiotic supplementation on inflammatory response and indicators of nutritional status in patients with morbid obesity. Adult individuals of both sexes with morbid obesity (body mass index ≥ 40 kg/m²) will be invited to participate in this randomized, placebo-controlled, triple-blind study. The participants will be divided into three groups: G1 - control group (placebo), G2 - prebiotic group and G3 - synbiotic group. The study will consist of four experimental time points: M0 - baseline and start of supplementation; M1 - after fifteen days of the first outpatient visit and fifteen days after the start of supplementation with prebiotic, synbiotic or placebo; M2 - after thirty days from the first outpatient visit and end of supplementation with prebiotic, synbiotic and placebo; and M3 - time after sixty days from the first outpatient visit. At all time points the inflammatory response will be assessed by determination of plasma cytokines (IL-1, IL-6, IL-10, TNF) and acute phase proteins (c-reactive protein and albumin), besides the evaluation of laboratory and anthropometric indicators of nutritional status. The primary endpoint will be the reduction in concentrations of inflammatory markers (cytokines and acute phase proteins). Investigators expect to contribute with new information in this field of knowledge, which may facilitate the clinical application of these results.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
April 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Erasmo Benicio Santos de Moraes Trindade

Doctor

Universidade Federal de Santa Catarina

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 years and less than 60 years
  • Body mass index (BMI)≥40kg/m2

Exclusion Criteria

  • Previous gastrointestinal diseases (e.g. cancer and inflammatory bowel disease)
  • Intolerances and/or food allergies (e.g. lactose intolerance and celiac disease)
  • Current use of anti-inflammatory drugs and/or antibiotics and/or immunosuppressants
  • Regular use of laxatives and/or appetite suppressants
  • Current or previous use (up to one month) of prebiotics, probiotics, synbiotics or products enriched with these food compounds
  • Intolerance to prebiotic and/or probiotic and/or synbiotic
  • Following a diet for weight loss in the last three months
  • Pregnant or breastfeeding
  • Following unusual diets (e.g. vegetarian, macrobiotic)
  • Alcohol dependence and/or illicit drugs dependence

Outcomes

Primary Outcomes

Cytokines

Time Frame: 2 months

Plasma IL-1, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha concentrations (pg/mL)

C-reactive protein

Time Frame: 2 months

Serum C-reactive protein concentrations (mg/L)

Secondary Outcomes

  • Folic acid(2 months)
  • Waist circumference(2 months)
  • Body mass index(2 months)
  • Triglycerides(2 months)
  • LDL-c(2 months)
  • Fasting insulin(2 months)
  • Brain-derived neurotrophic factor (BDNF)(2 months)
  • Growth hormone(2 months)
  • Iron(2 months)
  • HDL-c(2 months)
  • Glycated hemoglobin(2 months)
  • Total cholesterol(2 months)
  • Calcium(2 months)
  • Sodium(2 months)
  • Phosphorus(2 months)
  • Potassium(2 months)
  • Blood glucose(2 months)
  • Cortisol(2 months)
  • Adrenocorticotropic Hormone (ACTH)(2 months)
  • Vitamin B12(2 months)
  • Vitamin D(2 months)
  • Body weight(2 months)
  • Ghrelin(2 months)
  • Hepcidin(2 months)
  • Leptin(2 months)
  • Parathormone (PTH)(2 months)
  • Thyroid-Stimulating Hormone (TSH)(2 months)

Study Sites (1)

Loading locations...

Similar Trials